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background:  Cangrelor reduced ischemic events at 48 h, including ST, compared to clopidogrel in CHAMPION PHOENIX. We examined the efficacy 
of cangrelor in patients who received bivalirudin for PCI.
methods: Bivalirudin was used in 2,059/10,942 (18.8%) patients who also received cangrelor (n=1,014) or clopidogrel (n=1,045). PCI was 
performed for stable angina (66.3%), NSTEACS (22.6%) or STEMI (11.1%). Categorical data were compared by Chi-sq test. Kaplan-Meier curves for 
time to ST were compared by log-rank test.
results: At 48 h, death, MI, ischemia driven revascularization, or ST was lower with cangrelor vs. clopidogrel (48 [4.7%] vs 70 [6.7%]; OR 0.69, 
p=0.055). Death was the same (2 [0.2%] vs 2 [0.2%]; OR 1.03, p=0.98). MI was significantly reduced by cangrelor (37 [3.6%] vs 59 [5.6%]; OR 
0.63, p= 0.03), as was death/MI (39 [3.8%] vs 61 [5.8%]; OR 0.65, p=0.04). Cangrelor was associated with lower ST at 48 h (7 [0.7%] vs 15 
[1.4%]; OR 0.48, p= 0.10), based on reductions in the first 6 h, p=0.057 (Figure). GUSTO severe bleeding was low in both arms (2/1021 [0.2%] vs 
2/1055 [0.2%]; OR 1.03, p= 0.97), as were transfusions (3 [0.3%] vs 5 [0.5%]; OR 0.62, p=0.51). Results were consistent across stable angina, 
NSTEACS and STEMI (P=ns for interaction).
Conclusion: In patients receiving bivalirudin, cangrelor resulted in less MI and early ST compared to clopidogrel, suggesting that cangrelor may be 
of value in reducing the rate of acute ST noted with bivalirudin in trials of primary PCI, without increasing transfusion risk.
 
